STOCK TITAN

Savara Inc. - $SVRA STOCK NEWS

Welcome to our dedicated page for Savara news (Ticker: $SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Savara's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Savara's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.32%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.2%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
conferences
Savara Inc.

Nasdaq:SVRA

SVRA Rankings

SVRA Stock Data

650.12M
74.01M
6.17%
86.56%
2.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
AUSTIN

About SVRA

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com